Express News | Cabaletta Bio Announced Updated Data On Resecabtagene Autoleucel To Be Presented At 2025 Conferences; Covers Safety, Translational Data, Clinical Outcomes From First 10 Patients In RESET Program

BenzingaFeb 11 08:01 ET

Cabaletta Bio Announces Presentations Featuring Updated Clinical Data on Rese-cel at Upcoming Scientific Meetings in February

GlobeNewswireFeb 11 08:00 ET

Cabaletta Bio to Participate in Guggenheim's SMID Cap Biotech Conference

GlobeNewswireJan 29 08:00 ET

HC Wainwright & Co. Reiterates Buy on Cabaletta Bio, Maintains $25 Price Target

BenzingaJan 17 07:33 ET · Ratings

William Blair Maintains Cabaletta Bio(CABA.US) With Buy Rating

Moomoo NewsJan 13 17:31 ET · Ratings

William Blair Remains a Buy on Cabaletta Bio (CABA)

TipRanksJan 13 17:16 ET · Ratings